Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “TREAT”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3

Patterns of Radiation Therapy Practice for Patients Treated for Intact Cervical Cancer in 2005 to 2007: A Quality Research in Radiation Oncology Study

Purpose: To assess practice patterns and compliance with clinical performance measures for radiation therapy (RT) for patients with intact carcinoma of the cervix. Methods and Materials: Trained research associates reviewed the records of 261 randomly selected patients who received RT for cervix carcinoma between 2005 and 2007 from 45 facilities randomly selected after stratification by practice type. National estimates of patient and treatment characteristics were calculated from survey data using SUDAAN statistical software. Results: From the survey data, we estimated that only 8% of US facilities treated on average more than 3 eligible patients per year. No small or medium nonacademic facilities in the survey treated more than 3 eligible patients per year. Approximately 65.5% of patients began treatment in a facility that treated 3 or fewer eligible patients per year. Although 87.5% of patients had brachytherapy as part of their treatment, the proportion treated with external beam RT only was about double that estimated from the 1996 to 1999 survey. The use of high-dose-rate brachytherapy sharply increased, particularly in small nonacademic facilities. Overall, patients treated in nonacademic facilities were more likely to have incomplete or protracted treatment; 43% of patients treated in small nonacademic facilities did not have treatment completed within 10 weeks. Also, patients treated in facilities that treated 3 or fewer eligible patients per year were significantly less likely to receive concurrent chemotherapy than were patients treated in other facilities. Conclusion: Survey results indicate a disturbingly high rate of noncompliance with established criteria for high-quality care of patients with cervical cancer. Noncompliance rates are particularly high in nonacademic facilities, especially those that treat relatively few patients with intact cervical cancer.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Exosomes derived from thymic stromal lymphopoietin-treated dendritic cells regulate T helper 17/regulatory T cell differentiation via miR-21/Smad7 axis

Highlights: • Exosomes from TSLP-treated DCs promote Th17 differentiation. • Exosomes from TSLP-treated DCs inhibit Tregs differentiation. • MiR-21 is highly expressed in exosomes from TSLP-treated DCs. • Exosomal miR-21 regulates Th17/Treg differentiation by targeting Smad7. Thymic stromal lymphopoietin (TSLP) is associated with fungal keratitis. This work aims to investigate whether TSLP can regulate T helper (Th) 17 and regulatory T cell (Treg) differentiation. We separated dendritic cells (DCs) from peripheral blood of healthy volunteers. DCs were treated with TSLP to activate DCs, and exosomes were obtained. CD{sup +} T cells were incubated with exosomes from TSLP-treated DCs. We found that exosomes from TSLP-treated DCs notably promoted the proportions of Th17 cells and inhibited the proportions of Tregs in the CD4{sup +} T cells. Moreover, exosomes from TSLP-treated DCs enhanced the expression of retinoid-related orphan receptor γt (RORγt) and interleukin 17 (IL-17), and repressed the expression of forkhead box protein P3 (Foxp3) and interleukin 10 (IL-10) in the CD4{sup +} T cells. Furthermore, miR-21 was highly expressed in exosomes from TSLP-treated DCs. Exosomes from TSLP-treated miR-21-silenced DCs promoted Treg differentiation and suppressed Th17 differentiation. Smad7 up-regulation repressed Th17 differentiation and enhanced Treg differentiation, which was abolished by miR-21 overexpression. Smad7 overexpression rescued the effect of exosomes from TSLP-treated DCs on Th17/Treg differentiation. In conclusion, our article confirms that TSLP induces DCs to deliver miR-21 by secreting exosomes, and thus miR-21 regulates Th17/Treg differentiation by inhibiting Smad7. Thus, this work further reveals the biological role of miR-21 in fungal keratitis.

60 APPLIED LIFE SCIENCES↗

Treated fillers, compositions containing same, and articles prepared therefrom

The present invention includes a process for producing treated filler that includes (a) treating a slurry that includes untreated filler where the untreated filler has not been previously dried, with a treating composition that includes a treating agent, thereby forming a treated filler slurry, and (b) drying the treated filler slurry to produce treated filler. The treating agent can include an unsaturated fatty acid, derivative of an unsaturated fatty acid, or salt thereof. The present invention also is directed to treated filler prepared by the process, as well as rubber compounding compositions and tires including the treated filler.

Votruba-Drzal, Peter Lawrence↗

Nuclear characterization of a general-purpose instrumentation and materials testing location in TREAT

The Transient Reactor Test facility (TREAT) was constructed in the late 1950s, provided thousands of transient irradiations before being placed in standby in 1994, and resumed operations in 2017 in order to reclaim its crucial role in nuclear-heated safety research. The latter half of TREAT’s historic operation was best known for integral-scale testing of fuel specimens under postulated reactor plant accident conditions, while TREAT’s earlier history included extensive simpler phenomena identification tests that elucidated fundamental behaviors and paved the way for these integral-scale tests. Advances in modern computational capabilities and a resurgence of interest in novel reactor technology have created an opportunity for emphasizing modernized science-based and separate effects test capabilities once again at TREAT. An innovative approach to this type of testing has been developed to leverage minor radioactivity built-in during brief TREAT irradiations in low activation hardware to facilitate handling for materials and instrumentation testing. This capability, termed the Minimal Activation Retrievable Capsule Holder (MARCH) irradiation vehicle system, will be used for inaugural fueled experiments in TREAT’s modern era as well as novel approaches to study materials undergoing neutron irradiation and instrumentation development and qualifications. This paper describes a comprehensive nuclear characterization, obtained via computational modeling, of the test position in the MARCH system. Though directly applicable to the MARCH system, the results also provide general quantification of the nuclear performance of the reactor and potential test materials, crucial for evaluating potential experiment design and response in TREAT. The neutron and photon flux environment was calculated via MCNP with ENDF/B-VII.1 nuclear data. Wire heating rate and DPA calculations were also performed and evaluated using historic TREAT test data. Furthermore, these calculations were performed to provide steady-state baseline reference values typical in both half- and full-slotted TREAT core configurations, enabling design scoping analysis prior to development of more specific design testing needs and transient testing experimentation.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

Neutronic Consideration of TREAT Facility Fuel SiC Recladding

The Transient Reactor Test (TREAT) Facility is an air-cooled reactor composed of graphite-urania fuel encapsulated in zirconium alloy canisters and surrounded by ~2 ft (~61 cm) of nuclear grade graphite. The primary role of TREAT is to provide in-pile nuclear-heated safety research via transient testing [1]. Benchmark efforts have demonstrated sensitivity of TREAT neutronics models to graphite cross section data and key neutron poisons found in the fuel assemblies [2]. During fabrication of TREAT fuel assemblies, a small concentration of boron was inadvertently introduced with variable concentration into the aggregate of fuel blocks prepared for TREAT use. The concentration of boron, and its respective uncertainty, represent the most sensitive component in a neutronics study; unfortunately, nothing can be done to reduce or otherwise mitigate its impact. Hydrogen in the fuel blocks reduces the mean free path of the core and its true quantity and uncertainty is approximated. The hydrogen remains from pitch binder used in the fuel fabrication process and was not completely released due to incomplete fuel graphitization. Destructive fuel testing is necessary to quantify the actual hydrogen content and to improve benchmark model quality. A third neutron poison of some significance is the hafnium impurity in the Zircaloy-3 (Zry-3) assembly cladding. The quantity of hafnium is expected to be within nominal manufacturing limits for nuclear grade zircaloy. Recladding the fuel assemblies with material that is less neutron absorbing is expected to benefit reactor neutron economy. Moreover, TREAT’s total transient energy is restricted based on the rate of Zry-3 oxidation in TREAT’s air coolant environment. Hence, cladding with more benign air reaction kinetics could dramatically uprate the facility’s experimental capability. Silicon carbide (SiC) has been proposed as a candidate material for recladding TREAT assemblies, as SiC/SiC demonstrate favorable properties within nuclear environments [3]. The current operational limits of TREAT are restricted by the oxidation of Zry-3. Change of the cladding to SiC could feasibly double the current temperature limitation. Recladding opportunities allow for previously damaged fuel assemblies to be returned to service, as Zry-3 is not commercially available. The initial effort required to consider proceeding with any recladding effort is to neutronically characterize key reactor parameters while replacing Zry-3 with SiC. A characterization summary, with respective results, is provided herein.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

Baseline Assessment of TREAT for Modeling and Analysis Needs

TREAT is an air-cooled, graphite moderated, thermal, heterogeneous test facility designed to evaluate reactor fuels and structural materials under conditions simulating various types of nuclear excursions and transient undercooling situations that could occur in a nuclear reactor. After 21 years in a standby mode, TREAT is being re-activated to revive transient testing capabilities. Given the time elapsed and the concurrent loss of operating experience, current generation and advanced computational methods are being applied to begin TREAT modeling and simulation prior to renewed at-power operations. Such methods have limited value in predicting the behavior of TREAT without proper validation. Hence, the U.S. DOE has developed a number of programs to support development of benchmarks for both critical and transient operations. Extensive effort has been expended at INL to collect detailed descriptions, drawings and specifications for all aspects of TREAT, and to resolve conflicting data found through this process. This report provides a collection of these data, with updated figures that are significantly more readable than historic drawings and illustrations, compositions, and dimensions based on the best available sources. This document is not nor should it be considered to be a benchmark report. Rather, it is intended to provide one-stop shopping, to the extent possible, for other work that seeks to prepare detailed, accurate models of the core and its components. Given the nature of the variety of historic documents available and the loss of institutional memory, the only completely accurate database of TREAT data is TREAT itself. Unfortunately, disassembly of TREAT for inspection, assay, and measurement is highly unlikely. Hence the data provided herein is intended serve as a best-estimate substitute.

22 GENERAL STUDIES OF NUCLEAR REACTORS↗

Reactivation of the Transient Reactor Test (TREAT) Facility Neutron Radiography Program

Reactivation of the Transient Reactor Test (TREAT) Facility Neutron Radiography Program The Transient Reactor Test (TREAT) Facility is a 19,000 MW reactor located at the Idaho National Laboratory designed to perform transient testing on nuclear fuel experiments and materials. A neutron radiography facility was installed with the first radiograph being produced in 1967 that utilized the indirect (or transfer) method of neutron radiography to examine irradiated nuclear fuels and experiment test loops. The TREAT neutron radiography facility performed approximately 5,000 radiographs by the spring of 1977. The original radiography facility was upgraded in 1974-1975 to correct previous deficiencies and to improve capabilities. In 1986, an upgraded aperture was installed to increase the resolution of images followed by a major reactor upgrade completed in 1988. Overall, the existing neutron radiography system was in good working order. Originally built in 1958, the TREAT Facility was in operation until it was placed in a shutdown status in 1994. Following the Fukishima disaster and seeing a need for enhanced accident tolerant fuels, the United Stated Department of Energy decided to restart the TREAT facility and resume transient operations. In November 2017, the TREAT reactor was successfully restarted and is currently performing operational testing in preparation for initial experiment irradiations and transient testing. This paper reports on efforts to reactivate the TREAT neutron radiography station. A few minor shielding and system improvement upgrades have been completed along with the installation of a dedicated room for computed radiography equipment. Detailed beam characterization work was not performed following the last reactor upgrade. To characterize the neutron beam, gold foil activation measurements were made to determine an average neutron flux and flux profile. Additional multi-foil activation measurements will be made to calculate the energy spectrum. An open beam image will be taken that will provide the information about variations in the beam profile. A series of system qualification shots will also take place to accurately determine the effective image quality and image acquisition parameters. Full operational status of the TREAT neutron radiography system is scheduled for late summer of 2018.

36 MATERIALS SCIENCE↗

Status Report on Development of TREAT Water Loop

The Transient Reactor Test (TREAT) facility is a graphite based transient test reactor at the Idaho National Laboratory (INL). TREAT started operation in 1959 and performed thousands of transient irradiations for the primary purpose of nuclear fuel safety research. TREAT operations were suspended in 1994, and then, several years later, resumed reactor operations in 2017 to support development of advanced nuclear fuels. TREAT’s more recent historic focus had been for transients with relevance to sodium cooled fast spectrum reactors. TREAT’s first year of modern experiment work performed in 2018, however, saw the demonstration of new kinds of transients focused on light water reactor (LWR) needs including reactivity initiated accidents (RIA) and loss of coolant accidents (LOCA). The successful outcome of these efforts confirmed TREAT’s viability as a transient neutron source for LWR safety research. Since TREAT’s core is air cooled and provides no “built-in” thermal hydraulic boundary conditions for tests specimens, efforts have been underway to establish water-environment capabilities for testing specimens. Small static water capsules have been established to support single rod RIA testing where transient heating is brief. Similarly, deployment of enhanced water capsules with blowdown capability is nearing completion to support single rod LOCA testing. With careful experiment design these capsules can provide representative temperature response histories and water phase transitions for some experiment parameters. The capsule approach is appropriate for cost-effective early phase phenomena identification studies on novel fuels, or when the important test variables are thought to be fairly well understood so that they can be precisely targeted (such as they are for current fleet fuels with moderate burnup UO2 in uncoated zirconium alloy cladding). Due to lack of forced convection, however, the capsule approach cannot achieve representative temperature histories in all regions of the test fuel simultaneously (e.g. cladding and fuel centerline temperatures) while providing representative timing in water phase transitions. Nor can the capsule approach provide appropriate hydraulic conditions for multi-rod bundle testing. For these reasons, design and development has been undertaken for the TREAT Water-Environment Recirculating Loop (TWERL).

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

Glutamate co-transmission from developing medial nucleus of the trapezoid body - Lateral superior olive synapses is cochlear dependent in kanamycin-treated rats

Research highlights: {yields} Glutamate co-transmission is enhanced in kanamycin-treated rats. {yields} VGLUT3 expression is increased in kanamycin-treated rats. {yields} GlyR expression is decreased in kanamycin-treated rats. {yields} GlyR, VGLUT3 expression patterns are asymmetric in unilaterally cochlear ablated rat. -- Abstract: Cochlear dependency of glutamate co-transmission at the medial nucleus of the trapezoid body (MNTB) - the lateral superior olive (LSO) synapses was investigated using developing rats treated with high dose kanamycin. Rats were treated with kanamycin from postnatal day (P) 3 to P8. A scanning electron microscopic study on P9 demonstrated partial cochlear hair cell damage. A whole cell voltage clamp experiment demonstrated the increased glutamatergic portion of postsynaptic currents (PSCs) elicited by MNTB stimulation in P9-P11 kanamycin-treated rats. The enhanced VGLUT3 immunoreactivities (IRs) in kanamycin-treated rats and asymmetric VGLUT3 IRs in the LSO of unilaterally cochlear ablated rats supported the electrophysiologic data. Taken together, it is concluded that glutamate co-transmission is cochlear-dependent and enhanced glutamate co-transmission in kanamycin-treated rats is induced by partial cochlear damage.

60 APPLIED LIFE SCIENCES↗

Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy

Purpose: To quantify longitudinal changes in active bone marrow (ABM) distributions within unirradiated (extrapelvic) and irradiated (pelvic) bone marrow (BM) in cervical cancer patients treated with concurrent chemoradiation therapy (CRT). Methods and Materials: We sampled 39 cervical cancer patients treated with CRT, of whom 25 were treated with concurrent cisplatin (40 mg/m{sup 2}) and 14 were treated with cisplatin (40 mg/m{sup 2}) plus gemcitabine (50-125 mg/m{sup 2}) (C/G). Patients underwent {sup 18}F-fluorodeoxyglucose positron emission tomographic/computed tomographic imaging at baseline and 1.5 to 6.0 months after treatment. ABM was defined as the subvolume of bone with standardized uptake value (SUV) above the mean SUV of the total bone. The primary aim was to measure the compensatory response, defined as the change in the log of the ratio of extrapelvic versus pelvic ABM percentage from baseline to after treatment. We also quantified the change in the proportion of ABM and mean SUV in pelvic and extrapelvic BM using a 2-sided paired t test. Results: We observed a significant increase in the overall extrapelvic compensatory response after CRT (0.381; 95% confidence interval [CI]: 0.312, 0.449) and separately in patients treated with cisplatin (0.429; 95% CI: 0.340, 0.517) and C/G (0.294; 95% CI: 0.186, 0.402). We observed a trend toward higher compensatory response in patients treated with cisplatin compared with C/G (P=.057). Pelvic ABM percentage was reduced after CRT both in patients receiving cisplatin (P<.001) and in those receiving C/G (P<.001), whereas extrapelvic ABM percentage was increased in patients receiving cisplatin (P<.001) and C/G (P<.001). The mean SUV in pelvic structures was lower after CRT with both cisplatin (P<.001) and C/G (P<.001). The mean SUV appeared lower in extrapelvic structures after CRT in patients treated with C/G (P=.076) but not with cisplatin (P=.942). We also observed that older age and more intense chemotherapy regimens were correlated with a decreased compensatory response on multivariable analysis. In patients treated with C/G, mean pelvic bone marrow dose was found to be negatively correlated with the compensatory response. Conclusion: Patients have differing subacute compensatory responses after CRT, owing to variable recovery in unirradiated marrow. Intensive chemotherapy regimens appear to decrease the extrapelvic compensatory response, which may lead to increased hematologic toxicity.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Effects of Irrigating with Treated Oil and Gas Product Water on Crop Biomass and Soil Permeability

Demonstrating effective treatment technologies and beneficial uses for oil and gas produced water is essential for producers who must meet environmental standards and deal with high costs associated with produced water management. Proven, effective produced-water treatment technologies coupled with comprehensive data regarding blending ratios for productive long-term irrigation will improve the state-of-knowledge surrounding produced-water management. Effective produced-water management scenarios such as cost-effective treatment and irrigation will discourage discharge practices that result in legal battles between stakeholder entities. The goal of this work is to determine the optimal blending ratio required for irrigating crops with CBNG and conventional oil and gas produced water treated by ion exchange (IX), reverse osmosis (RO), or electro-dialysis reversal (EDR) in order to maintain the long term physical integrity of soils and to achieve normal crop production. The soils treated with CBNG produced water were characterized with significantly lower SAR values compared to those impacted with conventional oil and gas produced water. The CBNG produced water treated with RO at the 100% treatment level was significantly different from the untreated produced water, while the 25%, 50% and 75% water treatment levels were not significantly different from the untreated water. Conventional oil and gas produced water treated with EDR and RO showed comparable SAR results for the water treatment technologies. There was no significant difference between the 100% treated produced water and the control (river water). The EDR water treatment resulted with differences at each level of treatment, which were similar to RO treated conventional oil and gas water. The 100% treated water had SAR values significantly lower than the 75% and 50% treatments, which were similar (not significantly different). The results of the greenhouse irrigation study found the differences in biomass production between each soil were significant for Western Wheatgrass and Alfafla. The Sheridan sandy loam soil resulted in the highest production for western wheatgrass and alfalfa while the X-ranch sandy loam had the lowest production rate for both plants. Plant production levels resulting from untreated CBNG produced water were significantly higher compared to untreated conventional oil and gas produced water. However, few differences were found between water treatments. The biomass produced from the greenhouse study was analyzed for elemental composition and for forage value. Elemental composition indentified several interesting findings. Some of the biomass was characterized with seemly high boron and sodium levels. High levels of boron found in some of the biomass was unexpected and may indicate that alfalfa and western wheatgrass plants may have been impacted by either soil or irrigation water containing high boron levels. Plants irrigated with water treated using EDR technology appeared to contain higher levels of boron with increased levels of treatment. Forage evaluations were conducted using near infrared reflectance spectroscopy. The data collected show small differences, generally less than 10%, between produced water treatments including the no treatment and 100% treatment conditions for each plant species studied. The forage value of alfalfa and western wheatgrass did not show significant tendencies dependent on soil, the amount of produced water treatment, or treatment technology.

09 BIOMASS FUELS↗

Non-Fouling, Low Cost Electrolytic Coagulation & Disinfection for Treating Flowback and Produced Water for Reuse

Executive Summary This Final Report is composed of two major sections. The first section presents experimental results obtained in the laboratory during Budget Period 1. The second section presents results from the field test conducted during Budget Period 2. Laboratory Results This research investigated a novel electrochemical process for producing a ferric iron coagulant for use in treating flowback and produced water from hydraulic fracturing and oil production operations. The treatment system improves the effectiveness and lowers the cost of coagulation processes using Fe3+ as the coagulant. The electrolytic coagulant generation (ECG) system uses an electrochemical cell to produce acid and base from oilfield brine solutions. The acid is used to dissolve scrap iron to provide a Fe3+ coagulating agent. The base is used to neutralize the treated water. Compared to conventional electrocoagulation (EC), the main advantage of the ECG system is an order of magnitude lower cost for the source of iron. The second advantage over conventional EC is that it can deliver Fe3+ doses greater than 1 mM, since it is not limited by the amount of dissolved oxygen in the water required to oxidize ferrous to ferric iron. The capital costs for conventional EC and the ECG system are similar, but the operational costs for the ECG system are an order of magnitude lower than conventional EC. The combined costs for iron and electrical energy for treating 1 m3 of FPW with 1 mM Fe3+ is estimated to be $0.87 for conventional EC, and $0.087 for the ECG system. The estimated all-in cost for treating FPW with a 2 mM Fe3+ dose is $0.73/m3 ($0.12/bbl). Field Test Results The field test was conducted at the Paul Foster Central Tank Battery (CTB) in Lea County, New Mexico from November 10, 2022 through December 15, 2022. The feed water to the system was produced water from the Tatanka 1H formation. After approximately two weeks of testing, the initial batch of produced water had been treated and no untreated produced water was available. Thus, after this time, the feed water to the system consisted of previously treated water (i.e., recycled water). The recycled water had nearly all colloidal particles removed, and had a much lower alkalinity due to precipitation of carbonate minerals during the first pass through the system. Although the recycled water was not an ideal test solution due to its low particulate concentrations, its lower alkalinity did allow us to identify the main problem with the treatment system. The main problem with the treatment system was caused by the high alkalinity of the initial feed water (5.4 meq/L) that consumed a significant fraction of the electrochemically generated acid. This resulted in pH values exiting the iron contact tank that were too high to dissolve enough iron to effectively treat the produced water. Tests performed with recycled water with lower alkalinity did not have this issue, and dissolved iron concentrations greater than 20 mM could be achieved. One consistent observation was that effluent water from the iron contact tank was always free of particulates, even when fed with circumneutral solutions. This suggests that there is no need to dissolve high concentrations of iron if all the water to be treated is passed through the scrap iron canister. In this case, dissolved O2 and hypochlorous acid can promote sufficient iron corrosion to provide an effective coagulating agent – even in neutral pH water. This solves the problem resulting from highly alkaline produced water. Modifications to the design of the treatment system were made based on the field test results. These modifications will add minimal additional cost, and were tested in bench-scale laboratory experiments. In short-term testing, the modified treatment process was able to remove colloidal FeS particulates to levels below detection. Long-term, steady state testing will be required to determine whether the modified process is suitable for commercial treatment systems.

54 ENVIRONMENTAL SCIENCES↗

Neutronics Analysis of TREAT Multi-SERTTA Calibration Test Vehicle (Multi-SERTTA CAL)

Transient testing is a necessary step in the performance evaluation of Accident Tolerant Fuels (ATF) developed as part of the Fuel Cycle Research and Development Advanced Fuels Campaign initiated and supported by the United States Department of Energy (DOE-NE). These advanced fuels are expected to be used in future reactors or replace the current fuel design used in existing power reactors for enhanced performance and safety. Upon completion of a process proscribed by the National Environmental Policy Act, the Transient Reactor Test (TREAT) facility, located at Idaho National Laboratory (INL), was chosen by DOE-NE to provide the desired specialized testing. TREAT has successfully operated from start-up in 1959 to 1994 when it was placed on operational stand-by. Careful preparations are being made for operational readiness and TREAT is projected to resume testing no later than 2018. Past TREAT testing primarily focused on sodium-cooled reactor fuels (SRF). Test vehicle designs varied to accommodate testing needs ranging from separate effects tests to integral tests approaching simulation of actual reactor environment conditions including forced convection cooling. The current focus on light water reactor (LWR) ATF requires design of new experiment vehicles to accommodate the water/steam environment and associated complexities regarding desired energy deposition into the specimen and proper containment. The first set of experiments in TREAT restart is expected to be conducted with the Multi-SERTTA (Static Environment Rodlet Transient Test Apparatuses). Difficult to quantify and calculate integral and time dependent effects inherent in transient testing limit predictive modeling capability; therefore, calibration testing in TREAT prior to the actual experiment is necessary to empirically determine the effectiveness of core-to-specimen power coupling in order to achieve the desired energy deposition into the test specimen during a nuclear power transient. This has been done in the past, in part, by evaluating the difference in energy deposition into dosimeter wires subjected to various TREAT time dependent power conditions. These calibration tests were typically conducted in a test vehicle neutronically similar to the actual test vehicle, but more simplistic in design in order to quickly retrieve and analyze dosimeter wires and minimize containment structure costs due to several trials. Prior calibration testing for SRF experiments could be conducted without coolant as sodium has no notable neutronic effect on the core-to-specimen power coupling factor (PCF). Such is not the case with LWR fuel where water serves as both moderator and coolant. This presents a design challenge as the calibration test vehicle must retain heated, high-pressure water to preserve neutronic equivalence representative of near prototypic reactor conditions while allowing for quick retrieval of dosimeters. The solution to this challenge comes in the form of a thin walled dry well positioned through the center of the basic Multi-SERTTA design. Test vehicle reactivity worth and PCF are two important factors with respect to ascertainment of neutronic equivalence. Similarity in test vehicle reactivity worth is desired to avoid the need to change operational core rod positions in TREAT which could significantly alter neutron flux distribution and consequently power distribution throughout the core and into the test specimen. The geometry and composition of various materials within the experiment containment structure can also significantly alter the quality of neutron signal delivery from the core to the test specimen. Introduction of an Inconel tube, albeit very thin, is expected to impact PCF. Simple modifications to the CAL design may compensate for the anticipated change. Evaluation of these factors and proposed modifications through neutronics analysis serves to inform experiment design and is a valuable tool towards achieving the optimal CAL design.

21 SPECIFIC NUCLEAR REACTORS AND ASSOCIATED PLANTS↗

Restart of the Transient Reactor Test (TREAT) Facility Neutron Radiography Program

The TREAT radiography system is used to perform neutron radiography of fuels, experiments, and other specimens before and after irradiation within the TREAT reactor. The TREAT neutron radiography facility performed approximately 5,000 radiographs by the spring of 1977. Originally built in 1958, the TREAT Facility was in operation until it was placed in a shutdown status in 1994. Following the Fukishima disaster and seeing a need for enhanced accident tolerant fuels, the United Stated Department of Energy decided to restart the TREAT facility and resume transient operations. In November 2017, the TREAT reactor was successfully restarted and is currently performing operational testing in preparation for initial experiment irradiations and transient testing. This paper discusses efforts to reactivate the TREAT neutron radiography facility. To characterize the neutron beam, gold foil activation measurements were made to determine an average neutron flux and flux profile. An open beam image provides the information about variations in the beam profile. In conclusion, a series of system qualification radiographs have been acquired to determine the effective image acquisition parameters, resulting image quality, and the relationships between the two.

36 MATERIALS SCIENCE↗

Selection of Nuclear Fuel for TREAT: UO 2 vs U 3 O 8

The Transient Reactor Test (TREAT) that resides at the Materials and Fuels Complex (MFC) at Idaho National Laboratory (INL), first achieved criticality in 1959, and successfully performed many transient tests on nuclear fuel until 1994 when its operations were suspended. Resumption of operations at TREAT was approved in February 2014 to meet the U.S. Department of Energy (DOE) Office of Nuclear Energy’s objectives in transient testing of nuclear fuels. The National Nuclear Security Administration’s is converting TREAT from its existing highly enriched uranium (HEU) core to a new core containing low enriched uranium (LEU) (i.e., U-235< 20% by weight). The TREAT Conversion project is currently progressing with conceptual design phase activities. Dimensional stability of the fuel element assemblies, predictable fuel can oxidation and sufficient heat conductivity by the fuel blocks are some of the critical performance requirements of the new LEU fuel. Furthermore, to enable the design team to design fuel block and can specifications, it is amongst the objectives to evaluate TREAT LEU fuel and cladding material’s chemical interaction. This information is important to understand the viability of Zr-based alloys and fuel characteristics for the fabrication of the TREAT LEU fuel and cladding. Also, it is very important to make the right decision on what type of nuclear fuel will be used at TREAT. In particular, one has to consider different oxides of uranium, and most importantly, UO 2 vs U 3 O 8 . In this report, the results are documented pertaining to the choice mentioned above (UO 2 vs U 3 O 8 ). The conclusion in favor of using UO 2 was made based on the analysis of historical data, up-to-date literature, and self-consistent calculations of phase equilibria and thermodynamic properties in the U-O and U-O-C systems. The report is organized as follows. First, the criteria that were used to make the choice are analyzed. Secondly, existing historical data and current literature were reviewed. This analysis was supplemented by the construction and examination of the U-O and U-O-C phase diagrams at pressure close to negligent, thereby mimicking the conditions in which nuclear fuel is supposed to function inside the zirconium-based cladding in the reactor. Finally, our conclusion in favor of the UO 2 down selection was summarized and explained in the last Section of this document.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

Safety Analysis Challenges With Restart of the Idaho National Laboratory (INL) Transient Reactor Test (TREAT) Facility

Safety Analysis Challenges With Restart of the Idaho National Laboratory Transient Reactor Test (TREAT) Facility Dr. James Parry David Broussard Anthony LaPorta Douglas Gerstner Battelle Energy Alliance Idaho National Laboratory P.O. Box 1625/MS6194 Idaho Falls, ID 83415 The Transient Reactor Test Facility, commonly referred to as TREAT, is an air-cooled, thermal spectrum test reactor facility designed to: • Induce intense fission heating in the nuclear fuel being tested. • Test nuclear reactor fuels under severe reactor-accident conditions. • Study fuel meltdowns, metal-water reactions, interactions between overheated fuel and coolant, and the transient behavior of fuels for high-temperature systems. • Provide nondestructive test data through neutron radiography of fuel samples. • Allow for the detailed monitoring of the experiments during the test. TREAT was specifically designed to test prototypic-sized reactor fuel pins and bundles under transient power conditions. During its 35 year operating history, it conducted thousands of transient experiments. Today, these capabilities are required for predicting safety margins for next generation fuels and advanced reactor design safety. Even though TREAT has not operated since 1994, return to operable conditions and resumption of testing will occur in FY 2018. This paper discusses the unique challenges with performing and documenting the safety analyses that demonstrate that the TREAT restart may be performed safely. This includes a discussion of 1) the TREAT capability, design, and operations, 2) identification of the format and content of the required safety basis document changes, and 3) demonstration that the consequences of potential accidents during TREAT operations meet the consequence guidelines.

21 SPECIFIC NUCLEAR REACTORS AND ASSOCIATED PLANTS↗

Surrogate Models for TREAT Transient Calculations

The Transient Reactor Test Facility (TREAT) at Idaho National Laboratory (INL) is currently preparing for resumption of operation after more than 20 years in a long-term standby state. In parallel with preparation for operations and a new transient testing program, the DOENE Advanced Modeling and Simulation program (NEAMS) has been supporting the development of three-dimensional transient multi-physics modeling capabilities within the reactor physics application MAMMOTH. Recently, the MAMMOTH reactor physics team has begun development of uncertainty and sensitivity analysis for the TREAT core. This research will be used to support the analysis of reactor operation and experiment planning. Traditional approaches, i.e., Monte Carlo simulations, for such tasks require a large number of model evaluations under both steady state and transient conditions. However, exhaustive sets of sampling runs are simply not practical for TREAT since evaluations of each model can take a substantial amount of time. A solution to this problem is to build a surrogate model employing a smaller number of model evaluations. The surrogate model is designed to provide an accurate and fast approximation to the detailed TREAT model. In this manner, the surrogate model can be used in place of the TREAT transient model for uncertainty and sensitivity analysis at a fraction of the computational cost. The high dimensional model representation (HDMR) method is employed here for approximating the responses of interest in terms of functions of lower dimensions. This method has been implemented in RAVEN and all TREAT transient calculations are performed using the multiphysics code MAMMOTH. In addition, a code interface has also been developed in order to couple RAVEN with MAMMOTH. The surrogate model is then tested and compared for TREAT startup testing program Transient Test no. 15 core, and its accuracy is measured by its ability to estimate the mean, coefficient of variance, skewness, excess kurtosis and probability density function of the outputs of Transient Test no. 15 model, as well as root mean square error metric.

21 SPECIFIC NUCLEAR REACTORS AND ASSOCIATED PLANTS↗

Trigeminal Neuralgia Treated With Stereotactic Radiosurgery: The Effect of Dose Escalation on Pain Control and Treatment Outcomes

Purpose: To analyze the effect of dose escalation on treatment outcome in patients undergoing stereotactic radiosurgery (SRS) for trigeminal neuralgia (TN). Methods and Materials: A retrospective review was performed of 870 patients who underwent SRS for a diagnosis of TN from 2 institutions. Patients were typically treated using a single 4-mm isocenter placed at the trigeminal nerve dorsal root entry zone. Patients were divided into groups based on treatment doses: ≤82 Gy (352 patients), 83 to 86 Gy (85 patients), and ≥90 Gy (433 patients). Pain response was classified using a categorical scoring system, with fair or poor pain control representing treatment failure. Treatment-related facial numbness was classified using the Barrow Neurological Institute scale. Log-rank tests were performed to test differences in time to pain failure or development of facial numbness for patients treated with different doses. Results: Median age at first pain onset was 63 years, median age at time of SRS was 71 years, and median follow-up was 36.5 months from the time of SRS. A majority of patients (827, 95%) were clinically diagnosed with typical TN. The 4-year rate of excellent to good pain relief was 87% (95% confidence interval 84%-90%). The 4-year rate of pain response was 79%, 82%, and 92% in patients treated to ≤82 Gy, 83 to 86 Gy, and ≥90 Gy, respectively. Patients treated to doses ≤82 Gy had an increased risk of pain failure after SRS, compared with patients treated to ≥90 Gy (hazard ratio 2.0, P=.0007). Rates of treatment-related facial numbness were similar among patients treated to doses ≥83 Gy. Nine patients (1%) were diagnosed with anesthesia dolorosa. Conclusions: Dose escalation for TN to doses >82 Gy is associated with an improvement in response to treatment and duration of pain relief. Patients treated at these doses, however, should be counseled about the increased risk of treatment-related facial numbness.

62 RADIOLOGY AND NUCLEAR MEDICINE↗